GlassScriptPhysician profile
Tiffany Terhune
NPI 1851838320
$2,652.92
in general payments reported to CMS, 2019-2025
20 companies · $789 in 2025
The $789 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $267 · 2022: $63.43 · 2023: $914 · 2024: $620 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,322.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $600.02 | 2023-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $368.10 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $319.16 | 2021-2025 | Mounjaro, Jardiance, Humulin |
| Abbott Laboratories | $234.70 | 2023-2025 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $225.01 | 2023-2024 | Strensiq |
| Insulet Corporation | $168.69 | 2021-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.80 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $119.02 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $100.20 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $91.29 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $75.19 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $51.26 | 2021-2025 | Minimed 780g |
| Cequr Corporation | $33.95 | 2023-2024 | Cequr Simplicity |
| Amgen INC. | $32.36 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $28.03 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $20.33 | 2023 | Ilet Bionic Pancreas |
| Antares Pharma, INC. | $19.23 | 2023 | Nocdurna, Tlando, Xyosted |
| Abbvie INC. | $18.58 | 2023 | |
| Madrigal Pharmaceuticals | $14.37 | 2025 | Rezdiffra |
| Recordati_rare_diseases_inc. | $13.63 | 2024 | Isturisa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Terhune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.